Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Earnings per Share (Diluted) : $0.38 (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Earnings per Share (Diluted)?

Clinuvel Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was $0.14. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38.

Clinuvel Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2023 was $0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.41.

Clinuvel Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was $0.14. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38.

During the past 12 months, Clinuvel Pharmaceuticals's average EPS without NRIGrowth Rate was 10.40% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 21.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 14.20% per year.

During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 32.10% per year. The lowest was -120.60% per year. And the median was 11.80% per year.

Clinuvel Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Earnings per Share (Diluted) Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

0.25

0.23

0.37

0.28

0.40

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															0.08	0.20	0.16	0.24	0.14

Competitive Comparison of Clinuvel Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's PE Ratio falls into.

Clinuvel Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Clinuvel Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(20.54	-	0)	/	51.784
	=	0.40

Clinuvel Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(7.32	-	0)	/	51.585
	=	0.14

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.38

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Clinuvel Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.